Next, Dr Edwin Massey talking on the implementation of foetal RHD screening @NHSBT#BSH2019
Dr Massey reminds us that _RHD_ is the gene which may or may not be translated into RhD or D protein #BSH2019
Assay for screening 'over diagnoses' D negativity. Performed after 11 weeks gestation #BSH2019
False negative rate <0.1%. Risk of D pos baby in a 'missed' woman who is then alloimmunised AND has a further baby who is affected is so low that screening is deemed effective #BSH2019
For women already alloimmunised, different screening test is used and at 16+/40 as false negative has greater consequences #BSH2019
Can also test ffDNA for kell but done at 20 and 28/40 due to higher risk of false negativity. Recent audit shows only 22% repeated at 28/40 and 0.5% false neg rate. False negatives not always fed back so likely underestimate #BSH2019
ffDNA not done for HPA typing at @NHSBT - right shifted like kell so high risk of false negative rate. Rare occurrence (20/year in England) means QA would not be feasible; samples sent to Sanquin #BSH2019
Not all ffDNA tests are equal says Dr Massey. Important to know the sensitivity of the test and understand implications of false negative to inform clinical decision making (the same as for any test!) #BSH2019
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I had a personal request to do a tweetorial for the #haemSpRs on haemovigilance. Here goes. A #blooducation 🧵
Haemovigilance is a systematic surveillance of adverse reactions and adverse events related to transfusion’ with the aim of improving transfusion safety. transfusionguidelines.org/transfusion-ha…
We are very lucky in the UK to have @SHOTHV1, one of the first in the world to collate adverse events relating to transfusion - since the 1990s.
This morning I met with the chair and vice chair of the Midlands Regional Transfusion Committee, the Midlands Patient Blood Management Practitioner and the Customer Services Manager. What are their roles and what does the RTC do?
A #blooducation 🧵
RTCs serve to bring together Hospital Transfusion Committees to discuss best practice, implement new guidance and provide educational resources and events. They are run by clinicians and scientists working in hospitals, supported by @NHSBT.
Teaching our incoming haematology doctors today about transfusion in haematology patients. So who needs irradiated blood and why? A #blooducation🧵
All blood in the UK is leucocyte reduced (except granulocytes, but that’s another story). Despite this, a unit of red cells or platelets can have around a million residual white cells, mostly lymphocytes.
Every doctor starting in a new trust does transfusion training as part of their mandatory training. But why?
50ml ABO incompatible blood can kill a patient. ABO antibodies are naturally occurring (“everyone” has them) and they are IgM; they can activate complement and cause *immediate* intravascular haemolysis, causing release of free haem, endothelial activation, renal failure and DIC.
In most hospitals, blood banks require 2 samples (one may be historic) before releasing group specific (non-O) blood for a patient. This is to increase the chances of identifying a *wrong blood in tube* (pt whose blood's in the tube is not the pt whose details are on the outside)
It can be difficult to know where to start with transfusion – you can’t go on a ward round to find patients. BUT you do start with lab induction and your helpful #BMSes will show you around.
Excellent session on emergency paediatric transfusion #AABB20. Cyril Jacquot talking on pre hospital transfusion and summarising the literature.
28 day mortality following haemorrhage is higher in children than adults (unpublished data and substudies from PROPPR and PROMMTT)
Observational studies of large numbers of patients but with only very small numbers of paediatric patients suggest that pre hospital blood is not associated with an excess of transfusion reactions and in some studies is thought to have improved survival.
Whole blood, group O, high titre neg, used in paediatrics in Pittsburgh appears to be safe with no haemolysin-mediated haemoylsis in non group O patients (Leeper et al JAMA Pediatrics 2018) ncbi.nlm.nih.gov/pmc/articles/P…